Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility

H. Badali; S.A. Yazdanparast; A. Bonifaz; B. Mousavi; G.S. de Hoog; C.H.W. Klaassen; J.F.G.M. Meis

doi:10.1007/s11046-013-9631-6

Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility

H. Badali, S.A. Yazdanparast, A. Bonifaz, B. Mousavi, G.S. de Hoog, C.H.W. Klaassen, J.F.G.M. Meis

Onderzoeksoutput: Bijdrage aan wetenschappelijk tijdschrift/periodieke uitgave › Artikel › Wetenschappelijk › peer review

Samenvatting

Inter- and intraspecific genomic variability of 18 isolates of Veronaea botryosa originating from clinical and environmental sources was studied using amplified fragment length polymorphism (AFLP). The species was originally described from the environment, but several severe cases of disseminated infection in apparently healthy individuals have been reported worldwide. All tested strains of V. botryosa, identified on the basis of sequencing and phenotypic and physiological criteria prior to our study, were confirmed by AFLP analysis, yielding a clear separation of V. botryosa as a rather homogeneous group from related species. In vitro antifungal susceptibility testing resulted in MIC90s across all strains in increasing order posaconazole (0.25 mug/ml), itraconazole (1 mug/ml), voriconazole (4 mug/ml), terbinafine (4 mug/ml), caspofungin (8 mug/ml), anidulafungin (8 mug/ml), isavuconazole (16 mug/ml), amphotericin B (16 mug/ml), and fluconazole (32 mug/ml). Overall, the isolates showed a uniform pattern of low MICs of itraconazole and posaconazole, but high MICs for remaining agents. The echinocandins (caspofungin and anidulafungin) had no activity against V. botryosa. There was no statistically significant difference between susceptibilities of environmental (n = 11) and clinical (n = 7) isolates of V. botryosa (P > 0.05).

Originele taal-2	Engels
Pagina's (van-tot)	505-513
Tijdschrift	Mycopathologia
Volume	175
Nummer van het tijdschrift	5-6
DOI's	https://doi.org/10.1007/s11046-013-9631-6
Status	Gepubliceerd - 2013

Toegang tot document

10.1007/s11046-013-9631-6

Citeer dit

@article{54434def32214cc286df4841151e6e79,

title = "Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility",

abstract = "Inter- and intraspecific genomic variability of 18 isolates of Veronaea botryosa originating from clinical and environmental sources was studied using amplified fragment length polymorphism (AFLP). The species was originally described from the environment, but several severe cases of disseminated infection in apparently healthy individuals have been reported worldwide. All tested strains of V. botryosa, identified on the basis of sequencing and phenotypic and physiological criteria prior to our study, were confirmed by AFLP analysis, yielding a clear separation of V. botryosa as a rather homogeneous group from related species. In vitro antifungal susceptibility testing resulted in MIC90s across all strains in increasing order posaconazole (0.25 mug/ml), itraconazole (1 mug/ml), voriconazole (4 mug/ml), terbinafine (4 mug/ml), caspofungin (8 mug/ml), anidulafungin (8 mug/ml), isavuconazole (16 mug/ml), amphotericin B (16 mug/ml), and fluconazole (32 mug/ml). Overall, the isolates showed a uniform pattern of low MICs of itraconazole and posaconazole, but high MICs for remaining agents. The echinocandins (caspofungin and anidulafungin) had no activity against V. botryosa. There was no statistically significant difference between susceptibilities of environmental (n = 11) and clinical (n = 7) isolates of V. botryosa (P > 0.05).",

author = "H. Badali and S.A. Yazdanparast and A. Bonifaz and B. Mousavi and {de Hoog}, G.S. and C.H.W. Klaassen and J.F.G.M. Meis",

note = "Reporting year: 2013",

year = "2013",

doi = "10.1007/s11046-013-9631-6",

language = "English",

volume = "175",

pages = "505--513",

journal = "Mycopathologia",

issn = "0301-486X",

publisher = "Springer Netherlands",

number = "5-6",

}

Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility. / Badali, H.; Yazdanparast, S.A.; Bonifaz, A.; Mousavi, B.; de Hoog, G.S.; Klaassen, C.H.W.; Meis, J.F.G.M.

In: Mycopathologia, Vol. 175, Nr. 5-6, 2013, blz. 505-513.

Onderzoeksoutput: Bijdrage aan wetenschappelijk tijdschrift/periodieke uitgave › Artikel › Wetenschappelijk › peer review

TY - JOUR

T1 - Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility

AU - Badali, H.

AU - Yazdanparast, S.A.

AU - Bonifaz, A.

AU - Mousavi, B.

AU - de Hoog, G.S.

AU - Klaassen, C.H.W.

AU - Meis, J.F.G.M.

N1 - Reporting year: 2013

PY - 2013

Y1 - 2013

N2 - Inter- and intraspecific genomic variability of 18 isolates of Veronaea botryosa originating from clinical and environmental sources was studied using amplified fragment length polymorphism (AFLP). The species was originally described from the environment, but several severe cases of disseminated infection in apparently healthy individuals have been reported worldwide. All tested strains of V. botryosa, identified on the basis of sequencing and phenotypic and physiological criteria prior to our study, were confirmed by AFLP analysis, yielding a clear separation of V. botryosa as a rather homogeneous group from related species. In vitro antifungal susceptibility testing resulted in MIC90s across all strains in increasing order posaconazole (0.25 mug/ml), itraconazole (1 mug/ml), voriconazole (4 mug/ml), terbinafine (4 mug/ml), caspofungin (8 mug/ml), anidulafungin (8 mug/ml), isavuconazole (16 mug/ml), amphotericin B (16 mug/ml), and fluconazole (32 mug/ml). Overall, the isolates showed a uniform pattern of low MICs of itraconazole and posaconazole, but high MICs for remaining agents. The echinocandins (caspofungin and anidulafungin) had no activity against V. botryosa. There was no statistically significant difference between susceptibilities of environmental (n = 11) and clinical (n = 7) isolates of V. botryosa (P > 0.05).

AB - Inter- and intraspecific genomic variability of 18 isolates of Veronaea botryosa originating from clinical and environmental sources was studied using amplified fragment length polymorphism (AFLP). The species was originally described from the environment, but several severe cases of disseminated infection in apparently healthy individuals have been reported worldwide. All tested strains of V. botryosa, identified on the basis of sequencing and phenotypic and physiological criteria prior to our study, were confirmed by AFLP analysis, yielding a clear separation of V. botryosa as a rather homogeneous group from related species. In vitro antifungal susceptibility testing resulted in MIC90s across all strains in increasing order posaconazole (0.25 mug/ml), itraconazole (1 mug/ml), voriconazole (4 mug/ml), terbinafine (4 mug/ml), caspofungin (8 mug/ml), anidulafungin (8 mug/ml), isavuconazole (16 mug/ml), amphotericin B (16 mug/ml), and fluconazole (32 mug/ml). Overall, the isolates showed a uniform pattern of low MICs of itraconazole and posaconazole, but high MICs for remaining agents. The echinocandins (caspofungin and anidulafungin) had no activity against V. botryosa. There was no statistically significant difference between susceptibilities of environmental (n = 11) and clinical (n = 7) isolates of V. botryosa (P > 0.05).

U2 - 10.1007/s11046-013-9631-6

DO - 10.1007/s11046-013-9631-6

M3 - Article

VL - 175

SP - 505

EP - 513

JO - Mycopathologia

JF - Mycopathologia

SN - 0301-486X

IS - 5-6

ER -

Veronaea botryosa: molecular identification with amplified fragment length polymorphism (AFLP) and in vitro antifungal susceptibility

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit